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Abstract 
 
Parkinson’s disease includes neuropsychiatric manifestations such as depression, 
anxiety, apathy, psychosis, and impulse control disorders that frequently remain 
undeclared by patients and caregivers or undetected by doctors. Given their substantial 
impact on patients and caregivers, as well as the existence of effective therapies for 
some of these disorders, screening has an important role. Instruments for screening have 
a particular methodology for validation and their performance is expressed in terms of 
accuracy compared with the diagnostic criterion. The present study reviews the 
attributes of the screening instruments applied for detection of the abovementioned 
neuropsychiatric symptoms in Parkinson’s disease. 
 
A “quasi-systematic” review was carried out on the basis of previous systematic 
reviews commissioned by the American Academy of Neurology and the Movement 
Disorder Society, with an update from a literature search (2005-2014).   
 
For depression, eleven scales and questionnaires were shown to be valid for screening 
use in Parkinson’s disease. The recently developed Parkinson Anxiety Scale and the 
Geriatric Anxiety Inventory have shown satisfactory properties as screening instruments 
for anxiety and the Lille Apathy Rating Scale for detection of apathy in Parkinson’s 
disease. No scale covers the needs of a screening for psychosis in this setting and, 
therefore, a specific scale should be developed. The Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease and the Questionnaire for Impulsive-
Compulsive Disorders-Rating Scale are valid for a comprehensive screening of impulse 
control disorders and the Parkinson’s Disease-Sexual Addiction Screening Test for 
hypersexuality. 
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Introduction 
 
Neuropsychiatric symptoms (NPS) are an important component of the clinical 
manifestations of Parkinson’s disease (PD).1,3 Furthermore, they are highly prevalent 
and increase the impact of the disease on patients, their caregivers, and society as a 
whole.4,5 
 
Studies on prevalence indicate that major depression is present in 5 to 20% of patients 
and minor depression in an additional 1 to 30%;6 anxiety in about 40%, with panic 
disorder from 13 to 30%;7 apathy in 40%;8 psychotic manifestations in 10 to 40% of 
patients on dopaminergic medication and in 5 to 10% of those not receiving this 
treatment;9 and impulse control disorders (ICDs) in 14%.10 
 
In spite of their importance, NPS associated with PD frequently remain undetected by 
doctors11 and undeclared by patients,12,13 preventing interventions aimed at alleviating 
these symptoms.  
 
It is for these reasons that routine screening has a role.14 Screening is carried out for 
detecting disorders before they are advanced, when earlier treatment may be associated 
with symptom improvement or a better prognosis, or while they remain hidden or 
confounded with another condition. However, screening is only effective if several 
criteria are met. Disease-related requirements for screening are that the disorder: (1) has 
a high enough prevalence or a long lasting preclinical phase, so that the chances of 
detection of the disorder are increased; (2) has potentially serious consequences for the 
patient if undetected and untreated; (3) has an acceptable and effective treatment or 
intervention; and (4) has a better course if treated after detection by screening as 
opposed to delayed treatment after routine clinical detection.15,16 
 
Screening instruments should not be used as definitive “diagnostic instruments”. When 
the gold standard for diagnosis (e.g., a detailed diagnostic interview) is too complex to 
apply, the use of a screening tool can act as a substitute in certain circumstances. Tests 
used for screening should have been validated before they are used, the validity being 
defined as the “extent to which its scores are related to an independent diagnostic 
criterion or gold standard”. In short, a screening test is valid if it efficiently 
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distinguishes healthy from sick individuals. However, this distinction is not easy, as 
many disorders or health conditions (e.g., disability) develop on a continuum between 
two extremes (healthy – sick) with an area of transition in which the true condition of 
the individual is unclear. 
 
Jaeschke et al. provided guidelines for validation studies of screening instruments,17 
including: (1) independent, blind comparison with the reference gold standard of 
diagnosis; (2) evaluation in an appropriate spectrum of patients, such as those usually 
seen in clinical practice; (3) application of the reference standard independently of the 
result with the index diagnostic test; and (4) test description in detail sufficient to allow 
replication or independent validation in a different group of patients. The non-
observance of these rules gives room for bias in the outcomes of the study. 
Overestimation of test performance, for example, is typically observed in the following 
scenarios: (1) case-control studies; (2) when different reference tests are applied to 
subjects who are positive and negative for the assessed test; (3) when the reference test 
is not applied in a blind manner; or (4) when there is no description of criteria for the 
test.18 
 
The outcome of the screening in relation with the gold standard is represented in a 
contingency (2x2) table for a binary situation. The parameters indicative of the quality 
of a screening test are derived from the data displayed in this table (Supplementary 
material).  
 
Usually, in the field of the NPS, screening instruments are rating scales that were 
initially designed for measurement of a continuous condition (e.g., the severity of a 
disorder) and later were compared with diagnostic criteria to determine a cut-off value 
using comparison to the gold standard. In clinical practice, identification of NPS in PD 
patients using extensive diagnostic scales is impractical, but the application of such 
scales on a subset of screened positive patients may reach higher performance 
standards. Cut-off points with appropriate balance between sensitivity and specificity 
can be useful for therapeutic decisions, an aspect related with the aforesaid disease-
related requirements (3 and 4) for screening procedure.  
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The objective of this manuscript is to present the results of a “quasi-systematic” review 
(selection criteria were explicit, but the quality of the studies was not evaluated) on the 
accuracy of the instruments used for screening of common and significant 
neuropsychiatric disorders in PD: depression, anxiety, apathy, psychosis, and ICDs. 
Screening tools for cognitive-, sleep-, and sexual-related disorders will be not 
considered in the present study to allow a more detailed review of those focused on the 
abovementioned disorders. 
 
 
Methods 
 
We reviewed the articles published by the Movement Disorder Society (MDS) Task 
Forces on systematic reviews of scales depression, anxiety, apathy, and psychosis, as 
well as the corresponding reports of the Quality Standards Subcommittee of the 
American Academy of Neurology. In addition, a search was carried out in PubMed for 
papers published since 2005 to December 2014 including the following terms: 
(Parkinson’s disease) AND (screening) AND (neuropsychiatric symptoms OR 
depression OR anxiety OR apathy OR psychosis OR psychotic OR impulse control 
disorders). Also, articles from reference lists of core articles and authors’ files were 
reviewed.  
 
In the search, 2296 articles with a related title were obtained; 146 were selected for 
abstract review; of which 69 were reviewed in detail (21 related with depression, 9 of 
them not included in previous reviews; 9 with anxiety, 4 of them not previously 
reviewed; 8 with apathy, 1 of them not included in previous reviews; 10 with psychosis, 
4 of them not previously reviewed; and 21 with ICDs). Six articles were previous 
systematic reviews; 9 were related with diagnostic criteria; and 54 were studies 
potentially providing screening outcomes.  
Selection criteria for articles review were: (1) systematic reviews or research articles; 
(2) focusing on testing screening properties of the instrument; (3) and providing, at 
least, cut-off point, sensitivity, and specificity values of the screening instrument for the 
aforementioned neuropsychiatric disorders in PD populations. 
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Sensitivity and specificity reflect the accuracy of the test and are intrinsic of the test, but 
standard values for these attributes have not been determined for generalized use. The 
predictive values indicate how the test performs in the population to which it is applied 
and are influenced by the prevalence of the condition in that population.19 Prioritizing 
efficiency of screening, a high sensitivity (for avoiding loss of affected cases) and 
positive predictive value (at a low “cost”) are favored. Subjects identified as “positive” 
by the screening test will be later assessed with the gold standard to confirm or refute 
the diagnosis.  
 
 
1. Depression 
 
Depressive symptoms are common in patients with PD, and a major contributor to 
quality of life.20 The characteristics of depression differ in some respects from those of 
depression in patients without PD, and new criteria have been proposed.21 In 2006, the 
Quality Standards Subcommittee of the American Academy of Neurology (AAN) 
reviewed the instruments for evaluation of depression, psychosis and dementia in PD.22 
In this paper, the Subcommittee established that “validated criteria for depression, 
psychosis, and dementia in PD do not exist. Hence, the identification of clinically 
relevant screening and diagnostic tools for depression, psychosis, and cognitive decline 
validated specifically in the PD population is necessary”. They reported the cut-off 
points providing the highest diagnostic accuracy of three frequently used scales: Beck 
Depression Inventory-I (BDI-I), Hamilton Depression Rating Scale (HAMD-17) and 
Montgomery-Asberg Depression Rating Scale (MADRS) (Table 1). The authors advice 
that HAMD-17 and MADRS appear to perform better than the BDI, but the studies 
furnishing the referred data were underpowered to determine superiority. The final 
recommendation was that BDI-I and HAMD (Level B) and MADRS (Level C) should 
be considered for screening of depression in PD. 
 
Also in 2006, Mondolo and coworkers published the validity results of the Geriatric 
Depression Scale (GDS) and the Depression subscale of the Hospital Anxiety and 
Depression Scale (HADS-D) for screening of depression in PD.23 Both scales showed 
good validity for screening of mood at a cut-off 10/11, although the results were better 
for the HADS as a whole (Table 1).  
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The topic was also reviewed in 2007 by the MDS Task Force on Depression Rating 
Scales in PD and the conclusion of this review was that 6 of the 10 reviewed scales 
were valid for screening purposes of depression in PD.24  The HAMD, MADRS, and 
GDS, but also BDI and HADS were judged to be valid for screening of depression in 
PD. Those studies meeting the inclusion criteria for the present review are shown in the 
Table 1. 
 
The GDS-15 showed higher sensitivity and similar positive predictive value compared 
to the Patient Health Questionnaire (PHQ-9) for major and minor depression in a study 
on 214 PD patients, but cut-off points were not displayed.25 Recently, Williams et al. 
2012, compared nine scales for screening of depression in PD: BDI-II, Center for 
Epidemiologic Studies Depression Rating Scale-Revised (CESD-R), GDS-30, Inventory 
of Depressive Symptoms–Patient (IDS-SR), PHQ-9, Unified Parkinson’s Disease 
Rating Scale-Depression (UPDRS-Depression), HAMD-17, Inventory of Depressive 
Symptoms-Clinician (IDS-C), and MADRS.26 The conclusion of their analysis was that 
the GDS-30 has several advantages on the other scales for depression screening in PD, 
although all of the studied scales were valid to this purpose, with exception of the 
UPDRS-Depression. Cut-off score and parameters of screening performance for each 
scale and comparison with previous studies are shown in the Table 1 of this article. 
 
To summarize, the high prevalence of depression in PD6 and the strong impact of this 
mood disorder on patients’ disability and quality of life 20,21 have made it objective 
target for research and treatment. As a consequence, a number of studies have been 
carried out to investigate the instruments for detection and evaluation of depression. A 
considerable proportion of them show satisfactory properties for screening of this 
disorder in PD patients showing high sensitivity (≥85%) combined with relatively high 
specificity (≥ 75%) and, therefore, are deemed suitable for screening use in PD. These 
scales are: GDS (15, 20, and 30 items), HADS-D, HAMD-17, IDS-C, MADRS, UK 
National Institute for Health and Clinical Excellence (NICE) screening questions, PHQ-
9, WHO-5, and Zung’s SDS (Table 1). Not many studies have directly compared the 
clinimetric properties of depression scales with the intention to assess whether one 
specific scale can be preferred over others. The largest of the few studies in this field 
was the one by Williams et al. who compared nine depression rating scales for their 
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screening performance.26 They reported that all of the included scales had good 
sensitivity and specificity, and that their performance did not differ much. As such, it is 
not possible to recommend the use of a specific scale or scales when screening for 
depression in PD patients, and the choice of instrument will depend largely on matters 
of convenience, time and cost.41  In clinical and research settings, the decision to 
routinely use an instrument is probably more important than the choice of instrument.  
 
 
2. Anxiety 
 
Anxiety disorders in PD have received less attention than depressive disorders, even 
though there is evidence that they are equally or more prevalent than depressive 
disorders, affecting up to 40% of PD patients. Anxiety is associated with increased 
subjective motor symptoms, more severe gait problems and dyskinesias, freezing and 
on/off fluctuations and a reduced quality of life.42 In addition, there is a large overlap 
with depression: 36 to 65% of PD patients that suffer from an anxiety disorder also 
suffer from a depressive disorder.43 
 
The properties of the instruments applied for assessment of anxiety in PD were 
reviewed by another MDS Task Force.43 Six scales were reviewed: the Beck Anxiety 
Inventory (BAI),44 the Hospital Anxiety and Depression Scale and its Anxiety subscale 
(HADS-A),45 the Zung self-rating Anxiety Scale (SAS)and the Anxiety Status Inventory 
(ASI, which is the observer rated version of the SAS),46  the Spielberger State Trait 
Anxiety Inventory (STAI),47 the Hamilton Anxiety Rating Scale (HARS),48 and section 
5 (anxiety) of the Neuropsychiatric Inventory (NPI).49 
 
None of these scales could be recommended and were classified as “suggested” scales, 
following the assessment criteria of the MDS, since at the time of the review these 
scales had not been specifically validated in PD. Therefore, the MDS Task Force 
recommended supplementary studies with these scales to obtain information about their 
validity in PD patients.43 Subsequently, a validation study was performed that included 
the most commonly used scales for screening for anxiety: the BAI, HADS and HARS. 
It was demonstrated that whereas some clinimetric properties of these scales were 
acceptable, such as inter-rater and test-retest reliability, known groups validity and score 
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distributions,  other properties were not satisfactory, such as convergent validity, 
factorial structure and notably construct validity (Table 2).50 Moreover, none of the 
scales had a good fit to the Rasch model in item response theory (IRT) analyses.51 
Consequently, none of these scales were considered appropriate screening instruments 
for anxiety in PD. 
 
Later, the same group demonstrated the particular profile of anxiety disorders in PD and 
the questionable validity of the DSM-IV criteria in capturing this profile. This fact 
challenged the content and construct validity of the existing anxiety rating scales in PD 
patients. Therefore, the development of a new specific scale for assessment of the 
anxiety disorders in PD was proposed and developed, funded by the Michael J. Fox 
Foundation for Parkinson’s Research.42 The Parkinson Anxiety Scale (PAS)includes 
subscales for persistent and episodic anxiety as well as for avoidance behaviour, and 
exists in both a patient- and a clinician-rated version.52 Although not specifically 
designed for screening or diagnosis, its capacity to this purpose was tested against the 
Mini International Neuropsychiatric Inventory (MINI) section for anxiety (Table 3).53 
This scale appeared to have superior sensitivity and specificity to use as screener or 
diagnostic scale for anxiety in PD, as well as a good fit to the Rasch model.54 Tables 2 
and 3 list the clinimetric parameters at the optimal cut-off (highest sum of sensitivity 
and specificity), but the cut-off may be adjusted to better suit the purpose of evaluation, 
screening or diagnosis.  
 
Another scale that was subsequently validated in PD patients is the Geriatric Anxiety 
Inventory (GAI). The authors report good test-retest reliability and known 
groupsvalidity. The optimal cut-off of for diagnosing any anxiety disorder was 6/7, with 
a sensitivity of 0.88 and a specificity of 0.86 (Youden index 1.74).55 
 
Anxiety and anxiety rating scales in PD have only recently received proper attention. 
The PAS (Table 3) is the only instrument specifically designed for use in PD patients, 
showing satisfactory clinimetric properties and good divergent validity with depression 
rating scales. Subscales are used to assess persistent (generalized and social) anxiety, 
episodic anxiety (panic) and avoidance behavior. In addition to the PAS, one generic 
anxiety rating scale, the GAI, has recently been validated and found to have acceptable 
screening properties. Other validated scales, the HADS, BAI and HARS, showed less 
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favourable attributes for validity and fit to the Rasch model (Table 2). These commonly 
used generic scales focus on different symptoms, with the HARS focusing more on 
symptoms of generalized anxiety and the BAI more on symptoms of panic. Therefore, 
they identify different patient groups and have low convergent validity. Also, they are 
less well able to separate depression from anxiety. 
 
Contrary to depression rating scales, not many validation studies of anxiety rating scales 
have been performed in PD patients, and conclusions in this review are often based on 
one single study, without replication studies supporting the findings. Additional 
research on the clinimetric properties of the reviewed scales is needed.  
 
In summary, the PAS and the GAI are considered useful instruments for screening of 
anxiety in Parkinson’s disease. 
 
 
3. Apathy 
 
Apathy is defined as a lack of motivation, characterized by reduced goal directed 
behaviour, reduced goal directed cognitive activity and reduced emotional responsivity 
(or anhedonia). It is frequently present in depression and dementia, but has also been 
recognized as an independent syndrome.56Another MDS task force reviewed the scales 
applied for assessment of apathy in PD.57 Six scales were reviewed: the Apathy 
Evaluation Scale (AES),58 the Apathy Scale (AS, an adapted version of the AES),59 the 
Lille Apathy Rating Scale (LARS),60section 7 (apathy) of the NPI,49and the Apathy 
Inventory (AI).61 
 
For three scales (AES, AS, and LARS), cut-off scores have been recommended to 
screen for “clinically relevant apathetic symptoms” (37/38; 13/14; and 16/17, 
respectively). Although (proposed) consensus diagnostic criteria for apathy have 
recently been formulated,56 only two studies have assessed the validity of apathy rating 
scales against these criteria. . In a study 62 on 130 PD patients, of which 42% with 
apathy, the LARS showed a sensitivity 80% with specificity 90% for a cut-off -14/-13 
to detect apathy as diagnosed with the Starkstein and Leentjens’ criteria.63 The other 
scales lack evidence on screening properties in PD patients. Good concurrent validity of 
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the LARS with proposed diagnostic criteria for apathy was also reported by Drijgers et 
al., who found a 81% agreement between the classification on the basis of the proposed 
criteria and a cut-off of -16/-17 on the LARS.64 Other apathy rating scales including the 
AI, AS and AES, have not been validated against the proposed diagnostic criteria and 
hence cannot be recommended as screening tool since information on sensitivity and 
specificity is lacking. 
 
While it is generally recognized that apathy is an important non-motor symptom with a 
potentially great impact on daily functioning and quality of life, it is still an evolving 
concept that has no firm base in any classification system. In the DSM5, apathy is only 
listed as a subtype of 'personality change due to a general medical condition', as well as 
a symptom of several unrelated disorders (APA, 2013).65 This uncertain status of apathy 
as symptom or syndrome hampers research. For the same reasons as in the assessment 
of depressive or anxiety syndromes, the authors recommend the use of the (proposed) 
diagnostic criteria alongside a rating scale for evaluation of apathy in research settings. 
The LARS was specifically developed for PD patients and is to date the best validated  
scale. It is worthwhile studying the clinimetric properties of other apathy scales since 
the LARS is extensive and time consuming, and therefore less suited for clinical use. 
 
 
4. Psychosis 
Psychosis is a major challenge in Parkinson’s disease and a key non-motor symptom.66 
These include hallucinations which are usually a result of spontaneous aberrant 
perceptions, misinterpretations of real perceptual stimuli usually called illusions, and 
delusions.67,68 In clinical practice, visual hallucinations appear to be the most frequent 
psychotic manifestation, with cross-sectional studies reporting visual hallucinations in 
approximately 25% of chronically dopaminergic drug treated PD subjects.69 
Development of intrusive and complex visual hallucinations constitute one primary risk 
factor for nursing home placement of the patient.70 Nonetheless, clinical studies indicate 
psychosis is often not declared in clinical practice and as such there needs to be a high 
degree of awareness.12Assessment of psychosis is complex and needs considerable 
clinical expertise. Furthermore, patients with severe psychosis are often in hospital or 
institutions and could have considerable comorbid problems (e.g., cognitive 
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impairment) and as such application of specific psychosis based tools could also be 
problematic.  
 
There are two relevant reviews on this topic by the Quality Standards Subcommittee of 
the AAN 22 and the MDS task force,71 respectively. The AAN Quality Standards 
Subcommittee stated that a gold standard for diagnosis of psychosis in PD was not 
available and, in addition, the only study testing a specific scale, the Parkinson 
Psychosis Rating Scale (PPRS),72 was a Class IV study. Therefore, evidence was 
insufficient to conclude the quality of this scale as a screening tool for psychosis in PD, 
and no recommendation was made. 
 
In the MDS task force review, the authors identified three scales that include specific 
probes to test the presence of a psychotic disorder. When that probe is positive, items 
for rating the severity of the psychotic disturbances are applied, but when the response 
to the probe is negative the corresponding items are skipped and the next probe is 
tested. The three identified scales were the Parkinson Psychosis Questionnaire (PPQ),73 
the Rush Hallucination Inventory,74 and the Neuropsychiatric Inventory (NPI).49  
 
The PPQ73 assesses drug-induced psychotic symptoms, hallucinations and illusions, 
delusions, and orientation. Compared with DSM-IV criteria and considered as 
“positive/negative” test for the presence of psychosis (n=50), showed a sensitivity 100% 
with a specificity 92%. The PPQ has been recently used in several studies on PD.75-77 
 
The Rush Hallucination Inventory74 and the NPI49 have not been formally tested in 
regard to its accuracy for identifying neuropsychiatric disorders in PD. 
 
As per the MDS task force, content validity of the reviewed scales was found to be 
insufficient, as none of them properly includes the complete variety of psychosis 
manifestations that can be present in PD. Consequently, recommendations and 
conclusions related to their use were similar to those of the ANA Quality Standards 
Subcommittee17 and none of these scales could be recommended for screening of 
psychotic disorders in PD. 
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To summarize, for psychosis, none of the existent scales covers the variety of psychotic 
disorders potentially affecting PD patients or has been formally tested with regard to its 
screening properties in this setting. Therefore, the development of a new, specific scale 
including all relevant aspects related with this construct and to be applied for screening 
and severity assessment has been proposed.71 
 
 
5. Impulse control disorders (ICDs) and related behaviors 
 
Impulse control disorders (ICDs) and related behaviors (e.g., dopamine dysregulation 
syndrome, punding and hobbyism) are relatively frequent in PD. They can be very 
disruptive and have serious consequences for patients and their relatives, but also can 
remain undeclared to doctors until the impact on the psychosocial aspects has reached 
an extreme level. Some screening instruments and rating scales are available, both for a 
wide range of ICDs or focused on a specific disorder. An important issue to consider 
when assessing ICD symptoms is that there may be discordance between patient and 
informant reporting.78 
 
The Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
(QUIP)79 is the only validated specific instrument for screening of ICBs and other 
compulsive behaviors in PD. It is a self-administered, 12-item questionnaire with three 
sections: ICDs, compulsive behaviors (hobbyism, punding, walkabout), and compulsive 
medication use. Each section includes at least an introductory question with definition 
of the screened disorders and examples. Existing criteria80-84 were used for testing the 
screening capacity of the respective sections. The recommended cut-off scores for each 
questionnaire component appear in the Table 4. 
 
A rating scale for ICD severity (frequency) assessment was derived from the QUIP, the 
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale 
(QUIP-RS).85 This scale has also four main questions (about thoughts, urges/desires, 
and behaviors) related to compulsive gambling, buying, eating, and sexual behavior, 
and another three focused on related disorders (medication use, punding, and 
hobbyism). For each disorder the total score runs from 0 to 16; the total for the four 
ICDs, from 0 to 64; and the total QUIP-RS ranges from 0 to 112. As for the QUIP, the 
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diagnostic validation was based on a semi-structured interview including existing or 
proposed criteria for each disorder.80-84 Results concerning diagnostic ability of the 
QUIP-RS are shown in the Table 4. 
 
Other instruments for the comprehensive screening of ICDs and related behaviors in PD 
have been not validated in PD patients specifically (e.g., the Minnesota Impulsive 
Disorders Interview)86 or their diagnostic attributes have not been specifically tested.  
 
Some of the tools potentially useful for screening of a particular ICD and used at least 
in a study of PD patientsare considered next.The South Oaks Gambling Screen 
(SOGS)87 has been extensively used in non-PD and PD populations, but to our 
knowledge there are no detailed studies on its sensitivity and specificity in PD. The 
McElroy criteria for compulsive buying,88 used as the gold standard for diagnosis of 
buying disorder and widely applied in studies on PD populations, as well as the 
Compulsive Buying Scale89 lack specific testing as screening tools in PD patients. 
 
The Shorter version of the Sexual Addiction Screening Test for PD (PD-SAST)90 is an 
adaptation (short form) of the Sexual Addiction Screening Test91,92 to PD patients. It 
comprises 5 items answered Yes/No by patients. The cut-off point for a person to be at 
risk of hypersexual disorder was 2/3, with a sensitivity 100% and specificity 93% for a 
diagnosis based on DSM-IV-TR clinical criteria.90 
 
The Clinician Punding Criteria and Rating Scale93 has been used in several studies on 
punding in PD and has been compared with the psychiatric diagnosis94 with good 
results. However, the screening properties of the scale are not sufficiently determined. 
This is also the case for the Punding Rating Scale,95 a modified version of the Clinician 
Punding Criteria and Rating Scale93for use in cocaine addicts.The Saving Inventory-
Revised96 is applied to assess hoarding disorder, but has been used only occasionaly in 
PD patients and has not been explored as a screening tool in this setting. 
A large number of studies have been conducted and instruments applied to ascertain the 
frequency and severity of ICDs and symptoms in different PD cohorts. Two 
instruments, the QUIP and QUIP-RS,79,85 have been found to be useful for a 
comprehensive screening of ICDs and related behaviors in PD populations. It can be 
advantageous to screen for multiple ICDs simultaneously, as these disorders are 
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frequently co-morbid97 and having co-morbid ICDs is associated with increased 
depression and worse quality of life.97,98 As a screening instrument the QUIP has 
limitations, including that nearly 40% of patients without an ICD diagnosis screen 
positive for an ICD, although it is possible that some of these “false positives” are 
experiencing subsyndromal ICD symptoms and warrant monitoring.  For screening 
instruments assessing only a single ICD, the PD-SAST (for hypersexuality) has 
satisfactory psychometric properties but requires further testing.90 
 
In conclusion, only the QUIP  and QUIP-RS for a comprehensive screening of ICDs 
and the PD-SAST for hypersexuality have been sufficiently demonstrated to be valid 
screening instruments in the setting of PD. 
 
 
Discussion 
This review outlined the psychometric properties of instruments used for screening of 
the most important neuropsychiatric disorders in PD. An additional important 
consideration with assessment of NPS, particularly with ICD symptoms or psychosis, is 
whether the information should be obtained from the patient or a knowledgeable 
informant (KI), and the responses obtained will depend on the amount of insight that the 
patient has into his/her behaviors, as well as the amount of information that the patient 
shares with a KI.  There are limited data comparing patient to informed other ratings in 
PD.78,99 Also, when using instruments and diagnostic criteria developed for the general 
population and subsequently applying them to PD patients, it is important to note that 
the phenomenology of NPS in PD may differ in important ways from those in the 
general population.  Clearly, there is a need for further research to improve screening 
instruments and rating scales, particularly for ICDs in PD, whether that be reliability 
and validity testing of existing instruments, testing of further psychometric properties or 
the development of new ones specifically for use in this population.   
 
It is also important to emphasize that the objective of a screening procedure is to 
identify potential (candidate) cases of a disorder, but not to make a definitive diagnosis. 
Efficient screening requires high sensitivity to avoid loss of cases with the disorder and 
this can be achieved by decreasing the proportion of false negatives (c/a+c) 
(Supplementary material) by lowering of the cut-off value. Nonetheless, a balance with 
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an acceptable specificity (a relatively low proportion of false positives, b/b+d) must be 
kept. A final diagnosis can however only be made based on clinical examination and 
diagnostic criteria. 
 
Limitations. For this review, the selection of papers was based on a literature search in 
only one database (PubMed), restricted to a decade (2005-2014) and to articles 
providing empiric data about screening of NPS other than cognitive, sleep and sexual 
disorders in PD. These are important limitations, but the paper’s purpose is to outline 
the state of the current literature on basic properties, accessible to professionals with 
activity in that setting.  
However, we have not attempted to review and assess the content validity and 
psychometric validity of the scales evaluated in this paper which is exclusively focused 
on their screening properties 
 
In conclusion, there are empirical data of screening validity for instruments assessing 
depression, anxiety, apathy, and impulse control disorders (comprehensive and 
hypersexuality) in PD populations, but not for psychosis. There is room for future 
studies in the field of NPS screening for testing their performance compared to 
diagnostic criteria or to develop specific instruments with appropriate validity for 
detecting NPS in PD patients.  
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